Pediatricians’ Group Urges That All Infants Get New RSV Shot
WEDNESDAY, Aug. 16, 2023 (HealthDay News) -- All infants should receive the new long-acting preventive monoclonal antibody for respiratory syncytial virus (RSV), the nation's leading pediatrics group said.
The American Academy of Pediatrics (AAP) urged that access to the new medication, called nirsevimab, be equitable. The new medication may not be immediately available in all clinical settings. For that reason, the AAP also recommended continued use of another monoclonal antibody product, palivizumab, during the upcoming RSV season for children at high risk for severe illness.
"Pediatricians are sadly familiar with the dangers of RSV and its devastating consequences for some families," AAP President Sandy Chung, M.D., said in an academy news release. "We are eager to offer all infants this protection and urge federal officials to see that it is made available and affordable in all communities."
The U.S. Food and Drug Administration approved nirsevimab under the brand name Beyfortus. It is also recommended by the U.S. Centers for Disease Control and Prevention.
Clinical trials showed that nirsevimab reduces the risk for RSV requiring medical care by 75 percent. All infants younger than 8 months born during or entering their first RSV season should receive a single dose of nirsevimab, the AAP said. Infants and children aged 8 through 19 months who are at increased risk for severe RSV disease and entering their second RSV season should also receive a single dose. Eligible infants and children who cannot access nirsevimab should instead receive palivizumab, which includes a series of monthly doses.
The AAP is calling for a comprehensive strategy to ensure equitable access in hospitals, birthing centers, and other medical practices. Chung called the lack of access to the product for all children "alarming." The AAP is concerned that families living in lower-income and underresourced communities and infants who are at greatest risk for severe RSV illness may face challenges accessing the medication.
Related Posts
Women Have Poorer Survival Than Men After Bypass Surgery
WEDNESDAY, March 8, 2023 (HealthDay News) -- Women are more likely than men to...
Shyness, Ages 12 to 16
Like quite a few parents, you may have recently taken a good look at your...
Mean Monthly BP Increased Among U.S. Adults During COVID-19
MONDAY, March 7, 2022 (HealthDay News) -- Among adults in the United States,...
En EE. UU., se reduce la concienciación de que el VPH provoca cáncer
MARTES, 18 de abril de 2023 (HealthDay News) -- El virus del papiloma humano...